Lazuna, Merlina .
HRN: 24-05-52 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/26/2024
CEFOTAXIME 500MG (VIAL)
10/26/2024
11/02/2024
ORAL
500mg
BID
S/P D&C
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes